Work

Association of CYP2D6*4 Polymorphism with the Steady- State Concentration of Haloperidol in Patients with Alcohol-Induced Psychotic Disorders

Year: 2025

Type: article

Abstract: Background: genetic polymorphism and CYP2D6 activity, as well as haloperidol efficacy and safety rates. Purpose: genetic polymorphism with the steady-state concentration of haloperidol in patients with acute alcohol-induced psychotic disorders (AIPDs). Material and methods: The study involved 100 male patients with AIPD (average age 41.4 ± 14.4 years) who received haloperidol by injections in a dose of 5-10 mg/day. The efficacy profile was assessed using a validated psychometric PANSS scale (Positive and Negative Syndrome Scale). Therapy safety was assessed using the internationally validated UKU (Side-Effect Rating Scale) and SAS (Simpson-Angus Scale for Extrapyramidal Symptoms) scales. Genotyping was performed with the real-time polymerase chain reaction. Results: ) 3.89 [2.92; 5.26], p = 0.010. Conclusion: genetic polymorphism has a statistically significant effect on the steady-state concentration of haloperidol.

Source: Psychopharmacology Bulletin

DOI: 10.64719/pb.4450

Authors: AA Parkhomenko, MS Zastrozhin, SA Pozdnyakov, VV Noskov, IA Zaytsev, VA Ivanchenko, NP Denisenko, KA Akmalova, V Yu Skryabin, EA Bryun, DA Sychev

Institutions: University of California, San Francisco, Russian Medical Academy of Continuous Professional Education, Ministry of Health of the Russian Federation, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare

Language: English

Topic: Pharmacogenetics and Drug Metabolism

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W4308555383

FWCI:

Cites: 16

Cited by:

Related to: 10